Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience

doi:10.4254/wjh.v9.i1.48

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9892)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

546

WORD

469

HTML

3899

Figures (1-2)

249

Tables (1-3)

215

Sum=5378

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

567

Download

1133

Sum=1700

Publishing Process of This Article

Item

Count

Browse

1282

Download

1532

Sum=2814

Jan 8, 2017 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (21)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Jan 8, 2017; 9(1): 48-56
Published online Jan 8, 2017. doi: 10.4254/wjh.v9.i1.48

Table 2 Virological suppression at on-treatment time-points (n = 92)

Follow-up (mo)	0	6	12	18	24	30	36
Patients with viral load n (%)	92 (100)	74 (80.4)	65 (70.7)	58 (63)	46 (50)	30 (32.6)	28 (30.4)
Virological suppression n (%)	18 (19.6)	41 (55.4)	45 (69.2)	46 (79.3)	37 (80.4)	26 (86.7)	25 (89.3)

“Patients with viral load” refers to the number of patients at each time point who had an available HBV DNA reading. “Virological suppression” refers to the number of patients with HBV DNA < 20 IU/mL. HBV: Hepatitis B virus.

Citation: Lovett GC, Nguyen T, Iser DM, Holmes JA, Chen R, Demediuk B, Shaw G, Bell SJ, Desmond PV, Thompson AJ. Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience. World J Hepatol 2017; 9(1): 48-56
URL: https://www.wjgnet.com/1948-5182/full/v9/i1/48.htm
DOI: https://dx.doi.org/10.4254/wjh.v9.i1.48